This study will demonstrate the diagnostic utility of PSMA PET among patients with CRC with liver metastasis.
The participants can voluntarily sign informed consent forms
The participants are male/female over 20 years old.
The participant is currently undergoing cancer staging based on the previous pathological diagnosis of colorectal cancer
The participants are confirmed liver metastasis by CT, abdominal ultrasound, MRI, and FDG PET/CT within 30 days before receiving PSMA-PET/CT.
The colorectal cancer participants was diagnosed other organs metastases with multiple organ metastases not only the liver.
The colorectal cancer participants have undergone any treate after diagnosis of liver metastasis.
The participants have suffered from liver dysfunction such as AST/ALT ratio >2、total bilirubin >1.5 mg/dL within 6 months.
The participants suffered stage IV chronic kidney disease (eGFR<30 mL/min/1.73 m2) within 6 months.
Primo Biotechnology Co., Ltd
Lead sponsor
Kaohsiung Chang Gung Memorial Hospital,Taiwan
Collaborator